Core Viewpoint - The company, Kingdawei, is committed to enhancing the marketing of its health supplement brand Doctor's Best in the domestic market, leveraging its international brand identity and full industry chain advantages to increase market penetration of key products like Coenzyme Q10, magnesium tablets, and anti-aging series [2] Group 1 - The company aims to strengthen the market penetration of its key products through various strategies, including team building, adjusting assessment goals, increasing marketing investments, and developing suitable products [2] - The company plans to steadily advance the brand building and value creation of its domestic health supplement brand "Jinlexin" while further improving its brand matrix layout [2]

Core Viewpoint - The company, Jindawei, emphasizes its strong R&D and manufacturing capabilities, leveraging synthetic biology as a foundational innovation engine to create a comprehensive biological manufacturing platform driven by microbial fermentation and enzyme catalysis, supported by chemical synthesis [2] Group 1: R&D and Manufacturing Strength - The company possesses robust R&D and manufacturing capabilities [2] - It utilizes synthetic biology as a core innovation engine [2] - The company has developed a complete technology chain from molecular design to green manufacturing [2] Group 2: Product Development and Market Potential - The company focuses on innovative health product raw material development [2] - It has strategically positioned itself in product categories with significant market potential, including coenzyme Q10, algal oil omega-3, and biological sweeteners [2]

Core Viewpoint - Coenzyme Q10 is experiencing increasing market demand due to its validated health benefits in cardiovascular health and anti-aging, with applications across various sectors including dietary supplements, food additives, pharmaceuticals, and cosmetics [2] Group 1: Market Demand - The market demand for Coenzyme Q10 is on a continuous growth trend [2] - Major consumer countries for Coenzyme Q10 include developed nations such as the United States and Japan [2] - Emerging markets like China are identified as having significant potential and market space for Coenzyme Q10 [2]

Core Viewpoint - The company, Jindawei (002626.SZ), is making significant progress in its Coenzyme Q10 expansion project, which is one of its main products, with the infrastructure nearing completion and an expected annual production capacity of 920 tons upon full operation [1] Group 1 - The company has announced the investor relations activity record regarding its Coenzyme Q10 product [1] - The infrastructure for the Coenzyme Q10 expansion project is nearly completed [1] - Once fully operational, the annual production capacity for Coenzyme Q10 will reach 920 tons [1]

Group 1: Company Overview and Product Development - The company is advancing its Coenzyme Q10 expansion project, with the main construction completed and an expected annual production capacity of 920 tons upon full operation [2][3] - The company utilizes advanced biological fermentation methods, ensuring high product quality while reducing unit production costs [3] Group 2: Market Outlook and Demand - The market demand for Coenzyme Q10 is growing, driven by its applications in cardiovascular health and anti-aging products [3] - Major consumer markets for Coenzyme Q10 include developed countries like the United States and Japan, with significant potential in emerging markets such as China [3] Group 3: Marketing Strategy - The company plans to enhance the marketing of its health supplement brand, Doctor's Best, leveraging its international brand presence and full industry chain advantages [3] - Strategies include increasing market penetration of key products like Coenzyme Q10 and magnesium supplements, alongside promoting potential products through team development and marketing investments [3] Group 4: Research and Product Pipeline - The company possesses strong R&D and manufacturing capabilities, focusing on synthetic biology as a core innovation driver [3] - Future product development includes areas with significant market potential, such as omega-3 from algae and biobased sweeteners, in addition to Coenzyme Q10 [3]

Core Insights - The pharmaceutical-grade fish oil market is experiencing significant growth due to its high purity levels of EPA and DHA, which are crucial for cardiovascular disease prevention and brain health maintenance [1][3][4] - The global demand for pharmaceutical-grade fish oil is projected to increase, with sales expected to reach 31,400 tons in 2024, an increase of 5.9% from 2023 [3][4] - In China, the pharmaceutical-grade fish oil market is also expanding, with sales anticipated to reach 5,500 tons in 2024, reflecting a growth of 25% from the previous year [4] Industry Definition and Characteristics - Pharmaceutical-grade fish oil is derived from fatty fish and is characterized by its high concentration of omega-3 fatty acids, specifically EPA and DHA, which are validated for specific medical purposes [2][3] - Unlike regular dietary supplements, pharmaceutical-grade fish oil is a prescription-level treatment product with strong clinical evidence supporting its efficacy [2] Current Industry Status - The pharmaceutical-grade fish oil industry is witnessing a surge in demand driven by increasing health awareness among consumers, an aging population, and rising chronic disease rates [3][4] - The market is expected to see a steady increase in sales, with global sales projected to reach approximately 31,600 tons by 2025 [3] Industry Chain - The industry chain consists of upstream raw materials such as herring, mackerel, sardines, and tuna, which are processed into crude fish oil [5] - The midstream involves the production of pharmaceutical-grade fish oil, which has the highest technical barriers [5] - Downstream applications include pharmaceuticals, clinical nutrition, and high-end dietary supplements [5] Development Environment and Policies - The pharmaceutical-grade fish oil industry in China is supported by national policies aimed at promoting and regulating the sector, including standards for food safety and specific regulations for omega-3 fish oil products [6][7] Competitive Landscape - The Chinese pharmaceutical-grade fish oil market is characterized by competition among international pharmaceutical giants, leading domestic raw material and manufacturing companies, and health supplement brands [7][9] - The market is consolidating as stricter regulations and higher technical barriers drive competition towards leading players [7] Development Trends - The industry is moving towards a new phase characterized by high quality, strong evidence, precision, and globalization, with trends indicating a shift towards more precise, diversified, and evidence-based applications [11]

| 证券代码：002626 | 证券简称：金达威 | 公告编号：2025-095 | | --- | --- | --- | | 债券代码：127111 | 债券简称：金威转债 | | 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司金达威生物技 术（江苏）有限公司、厦门金达威维生素有限公司，近日收到国家知识产权局颁 发的 1 件发明专利证书，具体情况如下： 发明名称：非特异性过加氧酶突变体及其应用和 25-羟基维生素 D3 的制备 方法 专利号：ZL 2024 1 1987116.9 专利申请日：2024 年 12 月 31 日 专利权人：金达威生物技术（江苏）有限公司 厦门金达威维生素有限公司 厦门金达威集团股份有限公司 专利权期限：二十年 特此公告。 厦门金达威集团股份有限公司 董 事 会 授权公告日：2025 年 12 月 02 日 本发明公开了一种非特异性过加氧酶突变体及其应用和 25‑ 羟基维生素 D3 的制备方法，大大提高了 25‑ 羟基 ...

Group 1 - The company, Jindawei, is actively advancing its energy drink-related business [2] - The company responded to investor inquiries on November 27 regarding its ongoing projects [2] - The information was sourced from Securities Daily [2]

Core Viewpoint - The company is focusing on promoting its new product, the Ergotheanine Photon Bottle, under the Doctor's Best brand, while acknowledging that it currently has a smaller market share compared to competitors [2]. Group 1: Product Development and Marketing Strategy - The Ergotheanine Photon Bottle is one of the new products launched this year by the Doctor's Best brand [2]. - The company plans to increase penetration among oral beauty consumers and will continue to expand its product matrix to cater to more segmented consumer needs and scenarios [2].

Core Viewpoint - The company Jin Dawei (002626.SZ) has introduced a new product, "Ergothioneine Photon Bottle," under the Doctor's Best brand, which is currently experiencing a small sales proportion among its various products [1]. Group 1 - The "Ergothioneine Photon Bottle" is one of the new products launched this year by the Doctor's Best brand [1]. - The sales contribution of the new product remains relatively low compared to the overall product range [1]. - The company plans to enhance penetration into the oral beauty market while expanding its product matrix to cater to more segmented consumer needs and scenarios [1].